Omnicell, Inc. (OMCL) Stock Analysis
Breakout setup
Healthcare · Health Information Services
Hold if already holding. Not a fresh buy at $42.19, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an... Read more
Hold if already holding. Not a fresh buy at $42.19, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Mixed signals. Hold existing position. Score 5.7/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity no date, semi cycle peak clear). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $42.19, but acceptable to hold if already in. Reason: mixed signals — some dimensions strong, others weak. Chart setup: Golden cross, above all MAs, RSI 68, MACD bullish. Mixed signals. Hold existing position. Target $53.32 (+26.4%), stop $38.52 (−9.5%), A.R:R 1.9:1. Score 5.7/10, moderate confidence.
Take-profit target: $53.32 (+28.7% upside). Target $53.32 (+26.4%), stop $38.52 (−9.5%), A.R:R 1.9:1. Stop-loss: $38.52.
Omnicell, Inc. trades at a P/E of 94.1 (forward 18.9). TrendMatrix value score: 6.4/10. Verdict: Hold.
14 analysts cover OMCL with a consensus score of 4.1/5. Average price target: $61.
What does Omnicell, Inc. do?Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and...
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.